結(jié)締組織生長(zhǎng)因子(CTGF)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)
CLIA Kit for Connective Tissue Growth Factor (CTGF)
CCN2; HCS24; IGFBP8; NOV2; Insulin-Like Growth Factor-Binding Protein 8; Hypertrophic Chondrocyte-Specific Protein 24; CCN Family Member 2
- 編號(hào)USCA010Po
- 物種Sus scrofa; Porcine (Pig，豬) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)2h, 40min
- 檢測(cè)范圍0.27-200ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.13ng/mL.
- 樣本類(lèi)型Serum, plasma and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 2117 ¥ 3024 ¥ 13608 ¥ 25704 ¥ 211680
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)結(jié)締組織生長(zhǎng)因子(CTGF)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的結(jié)締組織生長(zhǎng)因子(CTGF)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 96-104 | 99 |
| EDTA plasma(n=5) | 98-105 | 101 |
| heparin plasma(n=5) | 88-95 | 92 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的結(jié)締組織生長(zhǎng)因子(CTGF)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中結(jié)締組織生長(zhǎng)因子(CTGF)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 95-102% | 79-91% | 90-98% | 78-102% |
| EDTA plasma(n=5) | 93-102% | 78-93% | 82-103% | 98-105% |
| heparin plasma(n=5) | 80-98% | 83-105% | 84-98% | 85-92% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100μL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分鐘；
8. 讀數(shù)。
實(shí)驗(yàn)原理
將結(jié)締組織生長(zhǎng)因子(CTGF)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的結(jié)締組織生長(zhǎng)因子(CTGF)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的結(jié)締組織生長(zhǎng)因子(CTGF)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入底物。加入底物后會(huì)產(chǎn)生輝光型光信號(hào)。發(fā)射光強(qiáng)度和樣品中的結(jié)締組織生長(zhǎng)因子(CTGF)呈正相關(guān)。用化學(xué)發(fā)光儀測(cè)定相對(duì)光單位（RLU），計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Sus scrofa; Porcine (Pig，豬) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA010Po01 | 結(jié)締組織生長(zhǎng)因子(CTGF)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA010Po01 | 結(jié)締組織生長(zhǎng)因子(CTGF)多克隆抗體 | WB |
| ULAA010Po71 | 結(jié)締組織生長(zhǎng)因子(CTGF)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAA010Po21 | 結(jié)締組織生長(zhǎng)因子(CTGF)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA010Po | 結(jié)締組織生長(zhǎng)因子(CTGF)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA010Po | 結(jié)締組織生長(zhǎng)因子(CTGF)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA010Po | 結(jié)締組織生長(zhǎng)因子(CTGF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UPSA010Po01 | 結(jié)締組織生長(zhǎng)因子(CTGF)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| UKSA010Po01 | 結(jié)締組織生長(zhǎng)因子(CTGF)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Journal of Orthopaedic Research | Promotion of bone formation by naringin in a titanium particle-induced diabetic murine calvarial osteolysis model [PubMed: 19824055] |
| World Journal of Gastroenterology | Connective tissue growth factor hammerhead ribozyme attenuates human hepatic stellate cell function [PubMed: PMC2726461] |
| PLos One | Activation of JNK Signaling Mediates Connective Tissue Growth Factor Expression and Scar Formation in Corneal Wound Healing [Plosone: 0032128] |
| Clinical Biochemistry | Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy [ScienceDirect: S0009912012000987] |
| The Journal of Heart and Lung Transplantation | Connective tissue growth factor (CTGF/CCN2): A protagonist in cardiac allograft vasculopathy development? [PubMed: S1053249812010121] |
| Biomedical and Environmental Sciences | The Intervention Effect of Rosiglitozone in Ovarian Fibrosis of PCOS Rats [Besjournal: Source] |
| Disease Markers | Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis [PubMed: 22846210] |
| World Journal of Gastroenterology | Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis [PubMed: PMC3351780] |
| Journal of ethnopharmacology | Multitargeted protective effect of Abacopteris penangiana against carrageenan-induced chronic prostatitis in rats. [Pubmed: 24211397] |
| Radiation Oncology | Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy [Ro-journal: Source] |
| PLoS One. | Knock Out of S1P3 Receptor Signaling Attenuates Inflammation and Fibrosis in Bleomycin-Induced Lung Injury Mice Model [Pubmed:Pmc4157792] |
| European Journal of Heart Failure | Connective tissue growth factor and cardiac diastolic dysfunction: human data from the Taiwan Diastolic Heart Failure Registry and molecular basis by cellular and animal models [Pubmed:24464932] |
| Bone | Connective Tissue Growth Factor is a Target of Notch Signaling in Cells of the Osteoblastic Lineage [Pubmed:24792956] |
| American Journal of Pathology | Disruption of collagen homeostasis can reverse established age-related myocardial fibrosis [Pubmed:25701883] |
| J Gastroenterol | Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis [PubMed: 26190501] |
| Life Sciences | Suppression of connective tissue growth factor mediates the renoprotective effect of Sitagliptin rather than Pioglitazone in type 2 diabetes mellitus [Pubmed:27049870] |
| International Journal of Molecular Sciences | TGF-β and Physiological Root Resorption of Deciduous Teeth. [pubmed:28035998] |
| Inflammation Research | Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy [pubmed:27516211] |
| Heart & Vessels | Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR [pubmed:28004175] |
| British?Journal of Ophthalmology | The relationship between anti-vascular endothelial growth factor and fibrosis in proliferative retinopathy: clinical and laboratory evidence [pubmed:27531356] |
| Pathophysiology | Molecular mechanisms underlying fibrosis and elastin destruction in childhood interstitial lung diseases [pubmed:27686729] |
| Evidence-Based Complementary and Alternative Medicine | Cardioprotection against Heart Failure by Shenfu Injection via TGF-β/Smads Signaling Pathway [pubmed:28698735] |
| Heart and Vessels | Left ventricular reverse remodeling is not related to biopsy?detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR [10.1007/s00380-016-0930-y] |
| Cytokine | 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis. [pubmed:28460256] |
| Advanced Healthcare Materials | Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. [pubmed:29120858] |
| Life?Sciences | Sustained β-AR stimulation induces synthesis and secretion of growth factors in cardiac myocytes that affect on cardiac fibroblast activation [Pubmed:29107793] |
| International Journal of Psychophysiology? | Substrate Stiffness Influences the Time Dependence of CTGF Protein Expression in Müller Cells [Pubmed:30123889] |
| Journal?of?Cellular?Physiology | TGFβ mediates collagen production in human CRSsNP nasal mucosa‐derived fibroblasts through Smad2/3‐dependent pathway and CTGF induction and secretion [Pubmed: 30426494] |
| Journal of?Clinical?Medicine | Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with?… [Pubmed: 30413105] |
| Nature Communications | Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M [Pubmed: 31249305] |
| Cardiology | Circulating Connective Tissue Growth Factor Is Associated with Diastolic Dysfunction in Patients with Diastolic Heart Failure [Pubmed: 31466059] |
| Stem Cells International | CTGF Attenuates Tendon-Derived Stem/Progenitor Cell Aging [Pubmed: 31827530] |
| Pharmaceuticals | Small-Dose Sunitinib Modulates p53, Bcl-2, STAT3, and ERK1/2 Pathways and Protects against Adenine-Induced Nephrotoxicity [Pubmed: 33212804] |
| BMC?Veterinary Research | Lysophosphatidic acid as a regulator of endometrial connective tissue growth factor and prostaglandin secretion during estrous cycle and endometrosis in the?… [Pubmed: 32943074] |
| Revista Portuguesa de Cardiologia | MicroRNAs and ventricular remodeling in aortic stenosis [Pubmed: 32682570] |
| Manuscript title Microparticles Containing MiR-625-5p In Coronary Artery Reduce Myocardial Fibrosis After Myocardial Infarction [] | |
| Exp Gerontol | High carbohydrate high fat diet causes arterial hypertension and histological changes in the aortic wall in aged rats: The involvement of connective tissue growth?… [34455071] |
| Research Square | Hepatocyte-specific Smad4 deficiency alleviates liver fibrosis via the p38/p65 pathway [] |
